Century Therapeutics Raises $135M in Oversubscribed Financing for CNTY-813, a Potential Type 1 Diabetes Cure

Century Therapeutics just reminded the market that patience, precision, and a long memory matter. An oversubscribed $135M private placement does not happen by accident, especially not in biotech winters that chew up weaker balance sheets for sport. This is a company that has lived a few lifetimes already, and it shows. Founded in 2018 out of Versant Ventures, with the scientific gravity of Marcela V. Maus, M.D., Ph.D. and Hiromitsu Nakauchi, M.D., Ph.D., and built early by Founding CEO Lalo Flores, Ph.D., Century Therapeutics was never about quick dopamine hits. It was about building cells that behave.

The headline is CNTY-813, an iPSC-derived beta islet program aimed squarely at Type 1 diabetes, a disease that never clocks out. The deeper story is discipline. After a brutal 2025 reset, a terminated Bristol Myers Squibb collaboration, and a workforce reduction that forced clarity over comfort, Century Therapeutics chose focus. Not louder press. Not wider pipelines. Focus. The kind investors respect when the math has to work and the biology has to follow.

This financing was led by TCGX, with RA Capital Management back in the room and new conviction from Commodore Capital, Deep Track Capital, RTW Investments, Venrock Healthcare Capital Partners, and the T1D Fund. That mix matters. Specialists, crossover thinkers, and disease-driven capital all agreeing that engineered immune evasion and scalable iPSC manufacturing are not science projects anymore. They are infrastructure.

Brent Pfeiffenberger, Pharm.D., MBA, has been steady about what this moment represents. Cash runway into Q1 2029 buys time, but more importantly it buys sequencing. Chad Cowan, Ph.D. brings the muscle memory of building platforms that survive contact with regulators. Gregory Russotti, Ph.D. keeps the manufacturing story honest. Douglas Carr holds the financial line while the CFO seat remains interim. Megan Bilson makes sure the people left standing can actually run the distance.

There is something poetic about a company called Century betting on durability. iPSCs that self-renew. Allo-Evasion engineered to disappear from immune crosshairs. A diabetes program designed not for maintenance, but for relief. This is long-term thinking in an industry addicted to quarterly applause. Investors did not fund a moment. They funded a timeline. And timelines are where real companies are made.